Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Overlapping features of hepatic complications after hematopoietic cell transplantation in a rare T-cell lymphoma: A clinical challenge.
Nunzi A, Ciangola G, Cerroni I, Mezzanotte V, Trotta GE, Meconi F, Zizzari A, Rapisarda VM, Savino L, Brega A, Argirò R, De Angelis G, Mariotti B, Bonanni F, Meddi E, Gurnari C, Bruno A, Mangione I, Venditti A, Cerretti R. Nunzi A, et al. Among authors: cerretti r. Curr Res Transl Med. 2024 Jun;72(2):103436. doi: 10.1016/j.retram.2023.103436. Epub 2023 Dec 20. Curr Res Transl Med. 2024. PMID: 38277899
Response Rates and Transplantation Impact in Patients with Relapsed Acute Promyelocytic Leukemia.
Costa A, Gurnari C, Scalzulli E, Cicconi L, Guarnera L, Carmosino I, Cerretti R, Bisegna ML, Capria S, Minotti C, Iori AP, Torrieri L, Venditti A, Pulsoni A, Martelli M, Voso MT, Breccia M. Costa A, et al. Among authors: cerretti r. Cancers (Basel). 2024 Sep 21;16(18):3214. doi: 10.3390/cancers16183214. Cancers (Basel). 2024. PMID: 39335185 Free PMC article.
Venetoclax plus decitabine as a bridge to allogeneic haematopoietic stem-cell transplantation in older patients with acute myeloid leukaemia (VEN-DEC GITMO): final report of a multicentre, single-arm, phase 2 trial.
Russo D, Polverelli N, Bernardi S, Santarone S, Farina M, Borlenghi E, Onida F, Castagna L, Bramanti S, Carella AM, Sorasio R, Martino M, Alati C, Olivieri A, Beltrami G, Curti A, Vetro C, Leotta S, Mancini V, Terruzzi E, Bernardi M, Galieni P, Musto P, Cerretti R, Giaccone L, Skert C, Radici V, Vezzoli M, Calza S, Leoni A, Garuffo L, Bonvicini C, Pellizzeri S, Malagola M, Ciceri F. Russo D, et al. Among authors: cerretti r. Lancet Haematol. 2024 Nov;11(11):e830-e838. doi: 10.1016/S2352-3026(24)00241-2. Epub 2024 Sep 20. Lancet Haematol. 2024. PMID: 39312920 Clinical Trial.
Busulfan-fludarabine versus busulfan-cyclophosphamide for allogeneic transplant in acute myeloid leukemia: long term analysis of GITMO AML-R2 trial.
Cavallaro G, Grassi A, Pavoni C, Micò MC, Busca A, Cavattoni IM, Santarone S, Borghero C, Olivieri A, Milone G, Chiusolo P, Musto P, Saccardi R, Patriarca F, Pane F, Saporiti G, Rivela P, Terruzzi E, Cerretti R, Marotta G, Carella AM, Nagler A, Russo D, Corradini P, Bernasconi P, Iori AP, Castagna L, Mordini N, Oldani E, Di Grazia C, Bacigalupo A, Rambaldi A. Cavallaro G, et al. Among authors: cerretti r. Blood Cancer J. 2024 Aug 21;14(1):141. doi: 10.1038/s41408-024-01116-5. Blood Cancer J. 2024. PMID: 39168989 Free PMC article. Clinical Trial.
Risk-adapted MRD-directed therapy for young adults with acute myeloid leukemia: 6-year update of the GIMEMA AML1310 trial.
Venditti A, Piciocchi A, Candoni A, Arena V, Palmieri R, Filì C, Carella AM, Calafiore V, Cairoli R, de Fabritiis P, Storti G, Salutari P, Lanza F, Martinelli G, Curti A, Luppi M, Ingrosso C, Martelli MP, Cuneo A, Albano F, Mulè A, Tafuri A, Cudillo L, Tieghi A, Fracchiolla NS, Capelli D, Trisolini SM, Alati C, La Sala E, Maurillo L, Del Principe MI, Irno Consalvo MA, Divona MD, Ottone T, Cerretti R, Sconocchia G, Voso MT, Fazi P, Vignetti M, Buccisano F. Venditti A, et al. Among authors: cerretti r. Blood Adv. 2024 Aug 27;8(16):4410-4413. doi: 10.1182/bloodadvances.2024013182. Blood Adv. 2024. PMID: 38968139 Free PMC article. No abstract available.
Fatal acute graft-versus-host disease in Sézary Syndrome treated with Mogamulizumab and hematopoietic cell transplantation.
Trotta GE, Ciangola G, Cerroni I, Mezzanotte V, Nunzi A, Anemona L, Savino L, De Angelis G, Mariotti B, Bonanni F, Meddi E, Zizzari A, Rapisarda VM, Mangione I, Bruno A, Cantonetti M, Venditti A, Cerretti R. Trotta GE, et al. Among authors: cerretti r. Curr Res Transl Med. 2024 Sep;72(3):103452. doi: 10.1016/j.retram.2024.103452. Epub 2024 Apr 24. Curr Res Transl Med. 2024. PMID: 38718540
61 results